0001209191-21-024893.txt : 20210402
0001209191-21-024893.hdr.sgml : 20210402
20210402210011
ACCESSION NUMBER: 0001209191-21-024893
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210331
FILED AS OF DATE: 20210402
DATE AS OF CHANGE: 20210402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taylor Stacy L
CENTRAL INDEX KEY: 0001799081
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 21803571
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVENUE E SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-31
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001799081
Taylor Stacy L
C/O ADAPTIVE BIOTECHNOLOGIES
1551 EASTLAKE AVE E STE 200
SEATTLE
WA
98102
0
1
0
0
SVP and General Counsel
Common Stock
2021-03-31
4
M
0
1042
7.80
A
16078
D
Common Stock
2021-03-31
4
M
0
1771
6.55
A
17849
D
Common Stock
2021-03-31
4
M
0
1354
31.71
A
19203
D
Common Stock
2021-03-31
4
S
0
4167
40.00
D
15036
D
Stock Option (Right to Buy)
7.80
2021-03-31
4
M
0
1042
0.00
D
2029-04-23
Common Stock
1042
26042
D
Stock Option (Right to Buy)
6.55
2021-03-31
4
M
0
1771
0.00
D
2028-04-24
Common Stock
1771
21250
D
Stock Option (Right to Buy)
31.71
2021-03-31
4
M
0
1354
0.00
D
2030-02-13
Common Stock
1354
47396
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Stacy L. Taylor by Eric Billings as attorney-in-fact
2021-04-02